Ardelyx Inc. (ARDX) shares surged 7.72% in pre-market trading on Wednesday after the company announced that its collaboration partner, Fosun Pharma, received approval from China's Center for Drug Evaluation for tenapanor (marketed as Wan Ti Le) to control serum phosphorus levels in dialysis patients with chronic kidney disease (CKD).
This approval triggers a $5 million milestone payment to Ardelyx from Fosun Pharma under their licensing agreement. Ardelyx is also eligible to receive additional developmental and commercialization milestones of up to $100 million, as well as tiered royalty payments on net sales ranging from the mid-teens to 20 percent.
Tenapanor, a first-in-class phosphate absorption inhibitor, has the potential to address a significant unmet need in China, where approximately 76% of over one million patients on maintenance hemodialysis suffer from hyperphosphatemia, and the rate of achieving target phosphate levels is low.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.